Clonal hematopoiesis related TET2 loss-of-function impedes IL1β-mediated epigenetic reprogramming in hematopoietic stem and progenitor cells

J. McClatchy, R. Strogantsev, E. Wolfe, H. Y. Lin, M. Mohammadhosseini, B. A. Davis, C. Eden, D. Goldman, W. H. Fleming, P. Conley, G. Wu, L. Cimmino, H. Mohammed and A. Agarwal ()
Additional contact information
J. McClatchy: Oregon Health & Science University
R. Strogantsev: Oregon Health & Science University
E. Wolfe: Oregon Health & Science University
H. Y. Lin: Oregon Health & Science University
M. Mohammadhosseini: Oregon Health & Science University
B. A. Davis: Oregon Health & Science University
C. Eden: Oregon Health & Science University
D. Goldman: Oregon Health & Science University
W. H. Fleming: Oregon Health & Science University
P. Conley: Oregon Health & Science University
G. Wu: Oregon Health & Science University
L. Cimmino: Sylvester Comprehensive Cancer Center
H. Mohammed: Oregon Health & Science University
A. Agarwal: Oregon Health & Science University

Nature Communications, 2023, vol. 14, issue 1, 1-17

Abstract: Abstract Clonal hematopoiesis (CH) is defined as a single hematopoietic stem/progenitor cell (HSPC) gaining selective advantage over a broader range of HSPCs. When linked to somatic mutations in myeloid malignancy-associated genes, such as TET2-mediated clonal hematopoiesis of indeterminate potential or CHIP, it represents increased risk for hematological malignancies and cardiovascular disease. IL1β is elevated in patients with CHIP, however, its effect is not well understood. Here we show that IL1β promotes expansion of pro-inflammatory monocytes/macrophages, coinciding with a failure in the demethylation of lymphoid and erythroid lineage associated enhancers and transcription factor binding sites, in a mouse model of CHIP with hematopoietic-cell-specific deletion of Tet2. DNA-methylation is significantly lost in wild type HSPCs upon IL1β administration, which is resisted by Tet2-deficient HSPCs, and thus IL1β enhances the self-renewing ability of Tet2-deficient HSPCs by upregulating genes associated with self-renewal and by resisting demethylation of transcription factor binding sites related to terminal differentiation. Using aged mouse models and human progenitors, we demonstrate that targeting IL1 signaling could represent an early intervention strategy in preleukemic disorders. In summary, our results show that Tet2 is an important mediator of an IL1β-promoted epigenetic program to maintain the fine balance between self-renewal and lineage differentiation during hematopoiesis.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-43697-y Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-43697-y

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-43697-y

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().